Colgate-Palmolive is currently in the spotlight as the company is exploring a major strategic exit valued at over $1 billion. This move follows collaboration with Goldman Sachs advisors to sell its non-core brands, including Softsoap, Irish Spring, and Speed Stick.
Market Movement Reasons
This news comes at a time when Colgate-Palmolive's shares are facing challenges in returning to an upward trend and are currently down about 12% from their highest level since the beginning of the year. This strategic sale is seen as a way to reallocate capital towards higher growth areas such as oral care and Hill's Pet Nutrition. This move could also help offset margin pressure in North America.
Read more: Rexin Austin, Crowdstrike CEO, sells $11.88 million in shares
Technical Analysis and Financial Performance
From a technical perspective, Colgate-Palmolive's shares are currently trading below their key moving averages, and the Relative Strength Index (RSI) around 30 indicates severe selling pressure. However, the company pays a healthy dividend of 2.44%, which could help offset some of the technical momentum shortfall.
Despite this year's poor performance, investment institutions' confidence in Colgate-Palmolive shares remains strong. For example, Baird increased its stake in this consumer products company in the second half of 2026, and the National Pension Service of Korea also increased its stake during the same period.
Additionally, Corient Private Wealth purchased another 143,812 shares of the company in the second half of the year, bringing its total holdings in Colgate-Palmolive to about $60 million.
In terms of price-to-sales (P/S) ratio, the company is relatively cheaper at approximately 3.4 times compared to its competitor Procter & Gamble, which is about 3.9 times. Furthermore, Wall Street firms remain optimistic about Colgate-Palmolive's future.
Currently, the overall rating for Colgate-Palmolive shares stands at "average buy," with an average price target of around $160 indicating potential for more than a 10% increase from the current price.
Read more: Oil declines following increase in U.S. crude oil inventories and Saudi supply concerns · Cathie Wood buys shares of Garden Health and sells shares of Iridium
